Technology
Health
Pharmaceutical

Kiniksa Pharmaceuticals

236

$6.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-2.71%) Today
$0.00 (0.00%) As of 4:00 PM EST after-hours

Why Robinhood?

You can buy or sell KNSA and other stocks, options, ETFs, and crypto commission-free!

About KNSA

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Read More Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

CEO
Sanj K. Patel
Employees
111
Headquarters
Hamilton, Hamilton
Founded
2015
Market Cap
363.70M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
132.74K
High Today
$6.78
Low Today
$6.38
Open Price
$6.62
Volume
56.78K
52 Week High
$28.90
52 Week Low
$5.01

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Medical
2018 IPO
North America (Non-US/Canada)
North America

KNSA News

MarketWatchNov 8

Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals, Ltd. (KNSA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. on
0

KNSA Earnings

-$1.27
-$0.99
-$0.72
-$0.44
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Mar 5, Pre-Market

You May Also Like

VOYA
DMRC
IVOO
ADMS
PBCT
CELG
HFXE
TLDH
HII
IGIH
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy KNSA

Market Price$6.45
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell KNSA stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up